ERBB2 and triple-negative breast carcinoma: The drug was further screened against other breast cancer cell lines including MDA-MB-231 (triple negative breast cancer cells), AU565 (Her2 positive breast cancer cells), and BT-474 (triple positive breast cancer cells).